Fast Five Quiz: Immunosuppression for Kidney Transplantation

Ron Shapiro, MD


October 22, 2021

Lymphocyte-depleting polyclonal antibodies can be used for induction immunosuppressive therapy for kidney transplantation. This strategy should be considered for renal transplant recipients at high risk of delayed graft function, which can predict acute rejection.

It is recommended by the American Society of Transplant Surgeons to include a biologic agent as part of the initial immunosuppressive induction regimen for kidney transplantation, with a nondepleting monoclonal antibody as the preferred first-line option.

Learn more about biologic agents for immunosuppression in kidney transplantation.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.